Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 57 publications
Author Correction: Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.
Journal: Nature
Published: August 05, 2026
Oncolytic Virotherapy for Solid Tumors: Clinical Advances and Future Directions.
Journal: Surgical oncology clinics of North America
Published: March 28, 2026
Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.
Journal: Nature
Published: February 16, 2026
Pharmacologic reprogramming of virus-tumor crosstalk enhances measles virus antitumor activity in BRAF mutant colorectal cancer models.
Journal: Journal of experimental & clinical cancer research : CR
Published: January 27, 2026
Phase I Study of Oncolytic Virus VV1 as Monotherapy or in Combination with Avelumab in Patients with Relapsed Refractory Solid Tumors.
Journal: Cancer research communications
Published: January 12, 2026
MDX-2001-101 study protocol: a phase I/IIa, multicenter, first-in-human, open-label clinical trial evaluating MDX2001 monotherapy in patients with advanced solid tumors.
Journal: Future oncology (London, England)
Published: January 06, 2026
EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinoma.
Journal: ESMO open
Published: November 06, 2025
A phase 1B trial of vocimagene amiretrorepvec in patients with advanced solid tumors: Safety, tumor homing, and immune modulatory effects.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: March 03, 2025
Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 09, 2024
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study.
Journal: The Lancet. Oncology
Published: August 19, 2024
Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: May 30, 2024
Last Updated: 09/26/2026